ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Holdings Lifted by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. lifted its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 10.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 20,607 shares of the company’s stock after acquiring an additional 1,962 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in ARS Pharmaceuticals were worth $217,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Renaissance Technologies LLC raised its position in ARS Pharmaceuticals by 884.9% during the second quarter. Renaissance Technologies LLC now owns 124,100 shares of the company’s stock valued at $1,056,000 after buying an additional 111,500 shares during the period. The Manufacturers Life Insurance Company acquired a new position in shares of ARS Pharmaceuticals in the 2nd quarter valued at about $180,000. Creative Planning increased its holdings in shares of ARS Pharmaceuticals by 7.0% in the 3rd quarter. Creative Planning now owns 35,263 shares of the company’s stock valued at $511,000 after purchasing an additional 2,307 shares during the period. nVerses Capital LLC purchased a new stake in shares of ARS Pharmaceuticals in the third quarter worth approximately $30,000. Finally, Raymond James & Associates acquired a new stake in shares of ARS Pharmaceuticals during the third quarter worth approximately $2,969,000. Institutional investors and hedge funds own 68.16% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Raymond James increased their target price on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, January 14th. Cantor Fitzgerald reissued an “overweight” rating and set a $30.00 price objective on shares of ARS Pharmaceuticals in a research report on Tuesday, October 8th. Finally, Leerink Partners upped their target price on ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an “outperform” rating in a research report on Monday, January 13th. Four research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, ARS Pharmaceuticals has an average rating of “Buy” and an average target price of $26.00.

ARS Pharmaceuticals Trading Down 8.9 %

Shares of NASDAQ:SPRY opened at $13.02 on Monday. The stock has a market capitalization of $1.27 billion, a PE ratio of -25.53 and a beta of 0.96. ARS Pharmaceuticals, Inc. has a 1 year low of $6.13 and a 1 year high of $18.51. The firm has a fifty day moving average price of $12.50 and a 200 day moving average price of $13.11.

Insiders Place Their Bets

In other ARS Pharmaceuticals news, major shareholder James E. Flynn sold 528,456 shares of the business’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $18.04, for a total transaction of $9,533,346.24. Following the completion of the transaction, the insider now owns 5,274,735 shares of the company’s stock, valued at $95,156,219.40. The trade was a 9.11 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Brian Dorsey sold 25,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $12.30, for a total value of $307,500.00. Following the completion of the sale, the chief operating officer now directly owns 6,024 shares in the company, valued at approximately $74,095.20. This represents a 80.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,095,558 shares of company stock valued at $16,853,686 over the last quarter. Insiders own 40.10% of the company’s stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.